Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + famitinib versus camrelizumab alone or investigator-choice chemotherapy in recurrent or metastatic cervical cancer
CTR20202635Phase 2Completed
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in Cervical Cancer (CC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
camrelizumabfamitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20202635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202635.